Positive
"The expectation for this study, based on our prior clinical experience, is that HA-Irinotecan will provide improved clinical benefit to patients without increasing the burden of toxicity. While it is still early in the trial, the data presented to the DSMB is consistent with that expectation.”
Negative
slow recruitment
- Forums
- ASX - By Stock
- TSN
- ha-irinotecan phase 3 trial update
ha-irinotecan phase 3 trial update , page-3
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
NEWS
Antler Copper Project hits major permitting milestone – air quality permit advances to final review
Add TSN (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
TSN (ASX) Chart |
Day chart unavailable